BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 36780161)

  • 21. The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study.
    Hall D; Lawn W; Ofori S; Trinci K; Borissova A; Mokrysz C; Petrilli K; Bloomfield MAP; Wall MB; Freeman TP; Curran HV
    Psychopharmacology (Berl); 2024 Jun; 241(6):1125-1134. PubMed ID: 38416223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
    Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of oral Δ9-tetrahydrocannabinol and cannabidiol combinations on a sustained attention task in rats.
    Moore CF; Davis CM; Sempio C; Klawitter J; Christians U; Weerts EM
    Exp Clin Psychopharmacol; 2023 Oct; 31(5):881-887. PubMed ID: 36634015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effects of Δ
    Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
    Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.
    Nadulski T; Sporkert F; Schnelle M; Stadelmann AM; Roser P; Schefter T; Pragst F
    J Anal Toxicol; 2005; 29(8):782-9. PubMed ID: 16356335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.
    Sholler DJ; Zamarripa CA; Spindle TR; Martin EL; Kuntz D; Vandrey R; Grabenauer M
    J Anal Toxicol; 2022 Oct; 46(8):882-890. PubMed ID: 35770374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.
    Eichler M; Spinedi L; Unfer-Grauwiler S; Bodmer M; Surber C; Luedi M; Drewe J
    Planta Med; 2012 May; 78(7):686-91. PubMed ID: 22411724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vaporizing cannabis rich in cannabidiol on cannabinoid levels in blood and on driving ability - a randomized clinical trial.
    Egloff L; Frei P; Gerlach K; Mercer-Chalmers-Bender K; Scheurer E
    Int J Legal Med; 2023 Nov; 137(6):1713-1723. PubMed ID: 37626214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Field Sobriety Tests for Identifying Drivers Under the Influence of Cannabis: A Randomized Clinical Trial.
    Marcotte TD; Umlauf A; Grelotti DJ; Sones EG; Mastropietro KF; Suhandynata RT; Huestis MA; Grant I; Fitzgerald RL
    JAMA Psychiatry; 2023 Sep; 80(9):914-923. PubMed ID: 37531115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials.
    Arkell TR; Kevin RC; Vinckenbosch F; Lintzeris N; Theunissen E; Ramaekers JG; McGregor IS
    Addict Biol; 2022 Mar; 27(2):e13125. PubMed ID: 34936167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.
    Spindle TR; Zamarripa CA; Russo E; Pollak L; Bigelow G; Ward AM; Tompson B; Sempio C; Shokati T; Klawitter J; Christians U; Vandrey R
    Drug Alcohol Depend; 2024 Apr; 257():111267. PubMed ID: 38498958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
    Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
    Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.
    Hutten NRPW; Arkell TR; Vinckenbosch F; Schepers J; Kevin RC; Theunissen EL; Kuypers KPC; McGregor IS; Ramaekers JG
    Psychopharmacology (Berl); 2022 Nov; 239(11):3731-3741. PubMed ID: 36227352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study.
    Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
    Cannabis Cannabinoid Res; 2024 Feb; 9(1):230-240. PubMed ID: 35881851
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
    Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
    Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
    Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
    Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.
    Englund A; Oliver D; Chesney E; Chester L; Wilson J; Sovi S; De Micheli A; Hodsoll J; Fusar-Poli P; Strang J; Murray RM; Freeman TP; McGuire P
    Neuropsychopharmacology; 2023 May; 48(6):869-876. PubMed ID: 36380220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
    Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
    Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
    Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
    PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.